Scientist III - Bioconjugation (ADC) Process Development jobs in United States
cer-icon
Apply on Employer Site
company-logo

Exelixis · 1 day ago

Scientist III - Bioconjugation (ADC) Process Development

Exelixis is a biotechnology company focused on developing innovative therapies for cancer patients. The Scientist III, Bioconjugation (ADC) Process Development, will be responsible for the development of scalable and robust downstream ADC processes and support technology transfer efforts leading to clinical GMP manufacturing of ADCs.

BiotechnologyHealth CarePharmaceutical
check
H1B Sponsor Likelynote

Responsibilities

Technical knowledge at design, execution and data interpretation of experiments related to development, optimization, and scale-up of biologics with a focus on ADC Bioconjugation and Purification processes
Develop Subject Matter Expertise in bioconjugation (ADC) process development and manufacturing in support of CMC activities
Work closely with research function to understand relevant conjugation chemistries and transition bioconjugation process from research to CMC development
The ability to identify, evaluate, and implement new and existing technologies to improve process efficiency, control, and understanding
Experience in applying DOE and other advanced statistical techniques to design experiments (DoE) related to process development
Familiarity with authoring high-quality documents, including technical reports, SOPs, experimental protocols, drafting tech transfer related documents (process description, process flow diagrams, tech transfer reports, etc.) reviewing batch records, and sampling plans
The ability to contribute to MFG floor activities and provide scale up, technical support and troubleshooting to MFG groups at clinical and commercial manufacturing sites
Demonstrated ability to work effectively with CDMOs, is a plus
A familiarity with critically relevant areas such as analytical, formulation, and the general CMC scope for biologics is preferred

Qualification

Bioconjugation process developmentADC chemistryTechnical transfer for biologicsDesign of experiments (DoE)Purification methodsCross-functional collaborationProblem solvingInterpersonal skillsWritten communication

Required

Bachelor's degree in chemistry, biochemistry, pharmaceutical sciences, chemical engineering or related field and a minimum of 3 years of relevant industry experience; or
Master's degree in chemistry, biochemistry, pharmaceutical sciences, chemical engineering or related field and a minimum of 1 year of relevant industry experience; or
Equivalent combination of education and experience
Technical knowledge at design, execution and data interpretation of experiments related to development, optimization, and scale-up of biologics with a focus on ADC Bioconjugation and Purification processes
Develop Subject Matter Expertise in bioconjugation (ADC) process development and manufacturing in support of CMC activities
Work closely with research function to understand relevant conjugation chemistries and transition bioconjugation process from research to CMC development
The ability to identify, evaluate, and implement new and existing technologies to improve process efficiency, control, and understanding
Experience in applying DOE and other advanced statistical techniques to design experiments (DoE) related to process development
Familiarity with authoring high-quality documents, including technical reports, SOPs, experimental protocols, drafting tech transfer related documents (process description, process flow diagrams, tech transfer reports, etc.) reviewing batch records, and sampling plans
The ability to contribute to MFG floor activities and provide scale up, technical support and troubleshooting to MFG groups at clinical and commercial manufacturing sites
Ability to collaborate with cross-functional teams, both internally and with external CDMOs and partners
Ability to multi-task in a fast-paced dynamic environment while delivering high-quality work
Self-motivated, accountable, and inquisitive attitude with excellent interpersonal, presentation, and written communication skills
Creative thinker and complex problem solver with strong attention to details
A demonstrated ability to work both independently and as a member of local and global teams

Preferred

Direct experience designing and implementing experiments to evaluate bioconjugation processes, including ADCs, is preferred
Hands-on experience with ADC chemistry, reaction processes and purification methods (i.e. Tangential flow filtration, chromatography, etc.)
Demonstrated experience and working knowledge of technical transfer for Biologics manufacturing (bioconjugations), is a plus
Additional experience with the development and manufacturing of mAbs, bispecifics and/or linker-toxins used in ADC production, and familiarity with analytical methods, is a plus
A familiarity with critically relevant areas such as analytical, formulation, and the general CMC scope for biologics is preferred

Benefits

401k plan with generous company contributions
Group medical, dental and vision coverage
Life and disability insurance
Flexible spending accounts
Discretionary annual bonus program
Sales-based incentive plan
Opportunity to purchase company stock
Receive long-term incentives
15 accrued vacation days in their first year
17 paid holidays including a company-wide winter shutdown in December
Up to 10 sick days throughout the calendar year

Company

Exelixis

company-logo
Exelixis works is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases.

H1B Sponsorship

Exelixis has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (39)
2024 (25)
2023 (25)
2022 (28)
2021 (29)
2020 (15)

Funding

Current Stage
Public Company
Total Funding
$514M
Key Investors
Deerfield
2015-07-23Post Ipo Equity· $135M
2012-02-16Post Ipo Equity· $65M
2010-06-03Post Ipo Debt· $160M

Leadership Team

leader-logo
Michael Morrissey
President and CEO
linkedin
leader-logo
Christopher Senner
Executive Vice President and CFO
linkedin
Company data provided by crunchbase